Aura Biosciences, Inc. AURA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
-4.21
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$106.2M | — | -$85.2M | $136.9M |
| 2024 | — | -$86.9M | — | -$81.1M | $152.0M |
| 2023 | — | -$76.4M | — | -$64.6M | $225.8M |
| 2022 | — | -$58.8M | — | -$55.7M | $195.6M |
| 2021 | — | -$35.3M | — | -$34.5M | $152.3M |
| 2020 | — | -$22.2M | — | -$25.1M | -$108.7M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -4.21 (distress)
- Working capital / assets 0.775
- Retained earnings / assets -2.835
- EBIT / assets -0.666
- Equity / liabilities 4.211
Source: SEC EDGAR filings · CIK 0001501796 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.